Jump to content

Sara Brenner

From Wikipedia, the free encyclopedia
Sara Brenner
Acting Commissioner of Food and Drugs
Assumed office
January 24, 2025
PresidentDonald Trump
Preceded byRobert Califf
Personal details
EducationIowa State University
University of Iowa
University at Albany, SUNY
Scientific career
FieldsPreventative medicine, public health, nanomedicine
InstitutionsUniversity at Albany, SUNY
Office of Science and Technology Policy
U.S. Food and Drug Administration

Sara Brenner is an American preventive medicine physician serving as the acting commissioner of Food and Drugs at the U.S. Food and Drug Administration (FDA) since 2025. She held roles in academia and federal health policy, including as a senior policy advisor in the Office of Science and Technology Policy.

Education

[edit]

Brenner received B.S. in genetics, with a minor in philosophy, from Iowa State University​.[1] She earned a M.D. from the Roy J. and Lucille A. Carver College of Medicine at the University of Iowa and a M.P.H. in health policy and administration from the University at Albany, SUNY's School of Public Health​.[1]

Brenner completed her medical training in internal medicine at NorthShore University HealthSystem. She later specialized in preventive medicine and public health at the New York State Department of Health and SUNY Albany School of Public Health​.[1]

Career

[edit]

Brenner was a faculty member at the College of Nanotechnology, Science, and Engineering. She held multiple roles, including associate professor of nanobioscience, assistant vice president for nanohealth initiatives, and director of the MD–PhD program in nanomedicine​.[1] Her research focused on the applications of nanoscale and advanced materials in medicine and public health, as well as assessing the health impacts of exposure to engineered nanomaterials​.[1]

In 2016, she was included in the Albany Business Reviews "40 under 40" list where she stated that her role was "never boring or predictable".[2]

In 2018, Brenner joined the Office of Science and Technology Policy (OSTP) as a senior policy advisor, where she worked on biomedical science, health data interoperability, translational science, and the U.S. bioeconomy​​.[1][3] She was also involved in initiatives addressing the opioid epidemic in the United States and veterans' suicide prevention​.[1]

In 2019, Brenner joined the U.S. Food and Drug Administration (FDA), serving in various capacities. As the chief medical officer for in vitro diagnostics and associate director for medical affairs within the FDA Center for Devices and Radiological Health, she contributed to regulatory compliance, policy development, and advancing the safety and effectiveness of medical devices​.[1] Brenner played a role in the COVID-19 response, focusing on diagnostics, data quality, and technological innovation across government agencies​.[1]

On January 24, 2025, Brenner was named acting commissioner of Food and Drugs at the FDA.[4] She assumed this role following the departure of Robert Califf and will serve until a permanent commissioner is confirmed​.[4]

References

[edit]
  1. ^ a b c d e f g h i "Sara Brenner". Food and Drug Administration. 2025-01-24. Retrieved 2025-01-27.Public Domain This article incorporates text from this source, which is in the public domain.
  2. ^ "40 Under 40: Sara Brenner". www.bizjournals.com. Retrieved 2025-01-28.
  3. ^ Williams, Shawna (April 18, 2018). "Inside the OSTP: Q&A With a Senior Science Policy Advisor". The Scientist. Retrieved 2025-01-27.
  4. ^ a b Reuter, Elise (January 24, 2025). "Sara Brenner named acting FDA commissioner". MedTech Dive. Retrieved 2025-01-27.
Government offices
Preceded by Acting Commissioner of Food and Drugs
2025–present
Incumbent